Galectin-1 gene expression and methylation state in human T leukemia cell lines

Area of Science:

• Immunology
• Molecular Biology
• Cancer Biology

Background:

• Galectin-1 mediates T-cell apoptosis in activated T-cells and T-leukemia cell lines.
• The role of endogenous galectin-1 expression in cellular sensitivity to its apoptotic effects is not fully understood.

Purpose of the Study:

• To investigate the relationship between galectin-1 sensitivity and endogenous galectin-1 gene expression in T-cells and T-leukemia.
• To elucidate the epigenetic mechanisms regulating galectin-1 gene expression in sensitive versus non-sensitive cells.
• To explore the potential for therapeutic reactivation of galectin-1 gene expression.

Main Methods:

• Assessing galectin-1 sensitivity in T-cell lines.
• Quantifying endogenous galectin-1 gene expression levels.
• Analyzing promoter region methylation status using techniques like methylation-specific PCR or bisulfite sequencing.
• Treating non-expressing cells with the demethylating agent 5-azacytidine.

Main Results:

• T-cell lines sensitive to galectin-1 showed repressed endogenous galectin-1 gene expression.
• Non-sensitive T-cell lines expressed high levels of galectin-1.
• Gene repression in sensitive cells correlated with hyper-methylation of the galectin-1 promoter region.
• Transient treatment with 5-azacytidine resulted in irreversible demethylation and reactivation of the galectin-1 gene in non-expressing cells.

Conclusions:

• Cellular sensitivity to galectin-1 is inversely correlated with endogenous galectin-1 gene expression.
• Epigenetic silencing via promoter hyper-methylation is a key mechanism for galectin-1 gene repression in sensitive cells.
• Demethylating agents like 5-azacytidine can overcome epigenetic silencing, leading to sustained galectin-1 gene reactivation and offering potential therapeutic strategies.